Pei Kan

President & Cofounder
Pharmosa Biopharm Inc.

Dr. Kan graduated from National Tsinghua University in Taiwan and completed post-doctoral research at Tsukuba University in Japan. He served as Associate Director of the Taiwan Liposomal Company, a Researcher at the Biomedical Engineering Center of the Industrial Technology Research Institute, and a Researcher at Tsukuba University in Japan. He has worked in the pharmaceutical industry for more than 25 years, focused on pharmaceutical formulation technology and product development, published over 50 papers and more than 15 patents related to drug delivery systems, most of which have been used in clinical products. He has led the development of new formulation-based drug projects, and completed filing and listing of IND, BioIND, and ANDA products in Taiwan, China, the United States, Japan, and Europe. He is now the cofounder and president of Pharmosa Biopharm Inc.
 

Speech title & Synopsis

Emerging Company of the Year

Pharmosa Biopharm Inc. (PBI) is an R&D company focusing on improving clinical treatment regimen of existing medicines by utilizing extended-release formulation and device combination system for self-administration through 505(b)2 regulatory pathway. The development of drug and device combination products has gained its significance and been growing rapidly. It has become a trend that will be increasingly important in the future. However, the combination of the controlled release of complex formulations and pharmaceutical device is still a challenge. Being the front runner in this field, PBI is expected to play a significant role giving its proprietary formulation, technology, IP positioning and global strategies.

PBI is focused on developing treatments for diseases related to pulmonary and peripheral vasculature. Our two main flagship products are L606 and L608. L606 is currently undergoing Phase III clinical trials in US for treating rare disease Group 1 pulmonary arterial hypertension, while preparation of pivotal Phase III clinical trial application to US FDA and EMA for treating Group 3 pulmonary hypertension associated with interstitial lung disease (PH-ILD). L608 is undergoing Phase I clinical trials in Australia, with potential therapeutic indications including rare disease Group 1 pulmonary hypertension and systemic sclerosis-related Raynaud's phenomenon and digital ulcers (SSc-RP/DU).

In June 2023, an exclusive out-licensing agreement of L606 was signed with Liquidia Technologies, Inc. (hereafter referred to as Liquidia), granting Liquidia the rights for the development and commercialization of L606 new drug therapy for pulmonary hypertension in the North American market.